Monitor for any Qualified Financing announcement (≥$15M gross proceeds) which would trigger automatic conversion to 59.6% of common stock, causing severe dilution. Also watch for insider selling patterns and any alternative financing or strategic alternatives before March 2028 deadline.
Price Chart
Executive Summary
Biotricity entered into exchange agreements converting ~19.6 million shares, options, and warrants held by officers and directors into 1.96 million shares of new Series C Preferred Stock. The Series C stock carries 40 votes per share and automatically converts into 59.6% of common stock upon a $15M+ financing, or into 10 common shares per preferred share by March 2028 if no such financing occurs, representing massive potential dilution and control shift.
Key Facts
- 14,144,325 common shares, options to buy 3,992,427 shares, and warrants to buy 1,436,216 shares were exchanged for 1,957,297 Series C Preferred shares at a 10:1 ratio.
- Series C Preferred has a stated value of $2.35 per share and 40 votes per share.
- Upon a Qualified Financing (gross proceeds ≥ $15M), Series C automatically converts into 59.6% of the company's outstanding common stock.
- If no Qualified Financing by March 31, 2028, each Series C share may be converted into 10 common shares at the holder's option.
- Conversion shares are subject to a one-year lockup.
- Exchange holders include officers and directors of the company.
Financial Impact
Extreme potential dilution: Series C conversion could grant holders 59.6% of common equity upon a $15M+ financing. Current market cap is unknown but dilution is massive.
Risk Factors
- Massive dilution to existing common shareholders upon a Qualified Financing or voluntary conversion.
- Insider consolidation of voting control (40 votes per preferred share) could entrench management.
- Uncertainty around ability to raise $15M+ to unlock conversion terms; lockup period may limit liquidity.
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 6 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 8-K Filing (Primary) | 0001493152-26-020939 |
| Exhibit: ex3-1.htm | 0001493152-26-020939 |
| Document: form8-k.htm | 0001493152-26-020939 |
| Document: 0001493152-26-020939-index-headers.html | 0001493152-26-020939 |
| Document: 0001493152-26-020939-index.html | 0001493152-26-020939 |
| Document: 0001493152-26-020939.txt | 0001493152-26-020939 |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers